What Happens When You Stop Ozempic (The Data)

Video Description

Stop a GLP-1 and about two thirds of the weight loss comes back within a year. Three randomized withdrawal trials (SURMOUNT-4, STEP 1 extension, STEP 4) and a new BMJ 2026 systematic review of 37 RCTs and nearly 10,000 adults all land on the same signal. The cardiometabolic benefits, blood pressure, fasting glucose, lipids, drift back in parallel with the weight. The framing that actually fits the data: GLP-1s behave like a statin, where there is cumulative benefit during exposure. This month's Direct Line covers two subscriber questions. The first asks what the new BMJ paper on GLP-1 cardiovascular protection after cessation actually shows, and how GLP-1 durability compares to lifestyle-only interventions. The second asks how a postmenopausal woman newly diagnosed with osteopenia should structure her lifting. Full episode on BBM+ covers 8 additional subscriber questions. Join at https://barbellmedicine.supercast.com/ Timestamps 0:00 Intro 1:52 Q1: What happens when you stop a GLP-1 5:33 Lifestyle-only comparators: DPP, Look AHEAD, POUNDS Lost 8:15 Austin on the cessation conversation 1 2:41 BMJ 2026: weight and cardiometabolic regression 17:59 The statin framing 23:41 Austin: first 6 months off GLP-1 28:07 Q2: Osteopenia and heavy lifting 35:28 LIFTMOR protocol 38:00 Outro What you'll get in this episode: Why the "4x faster regain" headline is technically correct and practically misleading How lifestyle-only trials (DPP, Look AHEAD, POUNDS Lost) actually compare on durability What the new BMJ 2026 paper modeled for cardiometabolic regression after cessation Whether weight-independent GLP-1 benefits (SELECT, FLOW) persist off the drug The statin framing that changes the whole conversation about discontinuation Austin's clinical playbook for the first 6 months after GLP-1 cessation LIFTMOR protocol details: loading, frequency, exercise selection, safety signal What osteopenia actually is, what fragility fractures are, and why lifting light misses the point Next Steps For evidence-based resistance training programs: barbellmedicine.com/training-programs For individualized training consultation: barbellmedicine.com/coaching Explore our full library of articles on health and performance: barbellmedicine.com/resources To consult with Drs. Baraki or Feigenbaum email us at [email protected] Resources Aronne, Louis J., et al. "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial." JAMA, vol. 331, no. 1, 2024, pp. 38–48. https://jamanetwork.com/journals/jama/fullarticle/2812936 Wilding, John P. H., et al. "Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: The STEP 1 Trial Extension." Diabetes, Obesity and Metabolism, vol. 24, no. 8, Aug. 2022, pp. 1553–1564. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14725 Rubino, Domenica, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial." JAMA, vol. 325, no. 14, 2021, pp. 1414–1425. https://jamanetwork.com/journals/jama/fullarticle/2777886 West, Sam, et al. "Weight Regain After Cessation of Medication for Weight Management: Systematic Review and Meta-Analysis." BMJ, vol. 392, 7 Jan. 2026, article e085304. https://www.bmj.com/content/392/bmj-2025-085304 Budini, Brajan, et al. "Trajectory of Weight Regain After Cessation of GLP-1 Receptor Agonists: A Systematic Review and Nonlinear Meta-Regression." eClinicalMedicine, vol. 93, 4 Mar. 2026, article 103796. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00043-X/fulltext Lincoff, A. Michael, et al. "Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes." New England Journal of Medicine, https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 Perkovic, Vlado, et al. "Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes." New England Journal of Medicine, https://www.nejm.org/doi/full/10.1056/NEJMoa2403347 Knowler, William C., et al. "Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin." New England Journal of Medicine,https://www.nejm.org/doi/full/10.1056/NEJMoa012512 Look AHEAD Research Group. "Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes." New England Journal of Medicine, https://www.nejm.org/doi/full/10.1056/NEJMoa1212914 Sacks, Frank M., et al. "Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates." New England Journal of Medicine, https://www.nejm.org/doi/full/10.1056/NEJMoa0804748 Watson, Shelley L., et al. "High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial." https://onlinelibrary.wiley.com/doi/10.1002/jbmr.3284